Advertisement

Topics

Novartis Trial Shows Durable Remission Rates for Children with Leukemia

10:18 EDT 23 Jun 2017 | PharmPro

Novartis pivotal CTL019 6-month follow-up data show durable remission rates in children, young adults with r/r B-cell ALL. Data evaluating 63 patients demonstrate relapse-free survival and probability of survival in a majority of patients at six months.
Contributed Author: 
Novartis Pharmaceuticals Corp.

Original Article: Novartis Trial Shows Durable Remission Rates for Children with Leukemia

NEXT ARTICLE

More From BioPortfolio on "Novartis Trial Shows Durable Remission Rates for Children with Leukemia"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Pediatrics
Pediatrics is the general medicine of childhood. Because of the developmental processes (psychological and physical) of childhood, the involvement of parents, and the social management of conditions at home and at school, pediatrics is a specialty. With ...